What Flightpath Biosciences does

Flightpath Biosciences is a clinical-stage biotechnology company headquartered in Detroit, Michigan (with a Berkeley, California office) that develops precision antibiotics through its proprietary Targeted Bacterial Deletion™ platform. The platform is designed to selectively remove pathogenic gram-negative bacteria that drive inflammation, immune dysregulation, and tissue damage in infection-driven complex diseases, while preserving the healthy microbiome. The company targets a deliberately broad set of indications where specific gram-negative organisms are causally implicated: Lyme disease and post-treatment Lyme disease (Borrelia burgdorferi), colorectal cancer (Fusobacterium nucleatum), inflammatory bowel disease (adherent-invasive E. coli), periodontal disease (P. gingivalis and other keystone pathogens), bacterial vaginosis and endometriosis (Gardnerella vaginalis, Fusobacterium), and complicated urinary tract infections and sepsis (resistant E. coli, Klebsiella pneumoniae, Enterobacter cloacae). Its clinical-stage pipeline comprises FP530 (Forazemin), an orally bioavailable peptide deformylase inhibitor licensed from Northeastern University that is now the lead candidate; FP385 (lolevexin), a gut-restricted LolCDE inhibitor licensed from the University of Illinois; FP380, a systemic LolCDE inhibitor targeting AMR-driven cUTI and sepsis; and the previously prioritized FP-100 (hygromycin A), which was deprioritized in May 2026 due to insufficient oral bioavailability in human studies.

The underlying technology is sourced exclusively through academic licensing agreements rather than internally originated discovery: FP530 and FP-100 from Northeastern University's Antimicrobial Drug Discovery Center (led by scientific cofounder Kim Lewis, PhD), and FP385/FP380/lolamicin from the University of Illinois Urbana-Champaign. A co-development agreement with the Forsyth Institute extends FP-100's application into oral disease, and a prior Illumina Accelerator affiliation generated what the company describes as the largest clinical biomarker study in Chronic Lyme Disease.

Commercially, Flightpath is pre-revenue with no product sales, no licensing income, and no disclosed pricing. Its stated revenue model is future pharmaceutical commercialization, expected to be executed through partnerships with larger pharmaceutical companies for global distribution and commercialization rights following FDA approval. The company raised approximately $8 million in a Series A round closing in 2024 (with related SEC Form D activity), supported by Ann Arbor SPARK, the Michigan Innovation and Commercialization Fund, and disease-focused foundations including The Steven & Alexandra Cohen Foundation, Bay Area Lyme Foundation, and Global Lyme Alliance. With 1–10 employees and most assets at preclinical-to-Phase I stage, the company is best characterized as an early-stage clinical venture whose value will be determined by Phase II/III outcomes and partnership economics rather than near-term product revenue.

Name

Flightpath Biosciences

Legal name

Flightpath Biosciences, Inc.

Website

https://flightpath.bio

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing drug candidates through clinical trials with plans for FDA approval and commercialization. Revenue will be generated through product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Flightpath Biosciences is a clinical-stage biopharmaceutical company developing narrow-spectrum, microbiome-sparing antibiotic drug candidates through its proprietary Targeted Bacterial Deletion™ platform. The company licenses proprietary drug compounds from Northeastern University and the University of Illinois, advancing them through clinical trials to treat infection-driven complex diseases including Lyme disease, colorectal cancer, inflammatory bowel disease, periodontal disease, complicated UTIs, bacterial vaginosis, and endometriosis.

Product overview

Flightpath Biosciences is a clinical-stage biotechnology company pioneering a Targeted Bacterial Deletion™ platform for treating infection-driven complex diseases. The company is developing multiple targeted drug candidates: FP530 (Forazemin) as the current lead clinical-stage compound (peptide deformylase inhibitor for Lyme disease, periodontal disease, and reproductive tract diseases); FP385 (lolevexin, gut-restricted LolCDE inhibitor for IBD and colorectal cancer); FP380 (systemic LolCDE inhibitor for complicated UTI and sepsis); and previously developed FP-100 (hygromycin A) for Lyme disease before strategic refocusing due to bioavailability limitations. These precision therapeutics aim to eliminate pathogenic gram-negative bacteria while sparing the healthy microbiome.

Differentiator

Problem solved

Functional benefit

Brands

• Targeted Bacterial Deletion™: Proprietary platform technology designed to address infection-driven complex disease by selectively removing harmful gram-negative bacteria without negatively impacting the surrounding microbiome.

Products and services

• FP530 (Forazemin) A clinical-stage, orally bioavailable small molecule peptide deformylase inhibitor that selectively targets gram-negative bacteria including Fusobacterium nucleatum, Porphyromonas gingivalis, Treponema, Borrelia burgdorferi, Gardnerella vaginalis, and Helicobacter pylori, while preserving the healthy microbiome. Designed to eradicate gram-negative bacteria from the oral cavity, GI tract, and reproductive system for indications including Lyme disease, periodontal disease, bacterial vaginosis, and endometriosis.
• FP385 (lolevexin) A gut-restricted small molecule LolCDE inhibitor targeting Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae without disrupting healthy gut bacteria. Developed for AIEC-positive IBD and complicated colorectal cancers with intractable Klebsiella pneumoniae and/or E. coli infections.
• FP380 A systemic small molecule LolCDE inhibitor targeting Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae without disrupting healthy gut bacteria. Designed to address causal bacteria in complicated UTI and sepsis cases unresponsive to current medications due to antimicrobial resistance.
• FP-100 (Hygromycin A) An orally available, narrow-spectrum bactericidal compound with selective activity against Borrelia burgdorferi (Lyme disease), Treponemes (syphilis and gum disease), and Fusobacterium nucleatum (implicated in colorectal cancer and women's health issues). Licensed from Northeastern University; Phase I human dosing began in May 2024 before being deprioritized due to limited oral bioavailability in humans.

Quantifiable outcome

• FP-100 cleared B. burgdorferi infection in mice and was less disruptive to fecal microbiome than clinically relevant antibiotics
• +3 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Forsyth InstitutecoreStrategic or Co-development Partner · 3 October 2023Multi-indication and multi-year co-development agreement to develop new products and intellectual property beginning with Flightpath's orally bioavailable, narrow-spectrum antibiotic FP-100 for prevention and treatment of oral diseases. Leverages Forsyth's intellectual property, animal models, and clinical expertise in oral health.
• Northeastern UniversitycoreTechnology or IntegrationFlightpath licenses FP530 (Forazemin), a peptide deformylase inhibitor rediscovered by co-founder Kim Lewis, PhD, from Northeastern University's Antimicrobial Drug Discovery Center. This is the second license from Northeastern for Flightpath, following the earlier FP-100 license. Dr. Lewis serves as Head of Northeastern's Antimicrobial Drug Discovery Center.
• University of IllinoiscoreTechnology or IntegrationFlightpath licenses lolamicin, a selective, microbiome-sparing drug platform technology developed at the University of Illinois Urbana-Champaign. This platform technology targets the lipoprotein transport system in Gram-negative bacteria.
• Illumina AcceleratorsupportingOthersFlightpath Biosciences graduated from the Illumina Accelerator program and completed the largest and most comprehensive clinical biomarker study in Chronic Lyme Disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Iterum Therapeutics: Public clinical-stage developer of oral antibiotics targeting drug-resistant gram-negative infections, including complicated UTIs — the exact indication pursued by Flightpath's FP380 systemic LolCDE inhibitor. Overlapping mechanism class (novel small-molecule antibiotics) and identical patient population make Iterum the closest comparable peer.
• Spero Therapeutics: Clinical-stage antibiotic developer focused on novel mechanisms for MDR gram-negative infections (pulmonary, cUTI). Shares the same development model (clinical-stage biotech, single-target programs against resistant bacteria, reliance on pharma partnerships) and competes for the same hospital-based antimicrobial market as Flightpath's FP380.
• Entasis Therapeutics (an Innoviva company): Acquired by Innoviva in 2022; develops precision antibiotics for serious gram-negative infections, including lead programs targeting Enterobacterales and Pseudomonas. Direct mechanism overlap with Flightpath's gram-negative LolCDE inhibitors (FP385, FP380), targeting identical bacterial pathogens (E. coli, Klebsiella, Enterobacter).

Broad incumbents

• Paratek Pharmaceuticals (now Paratek / nonprofit): Developed and commercialized omadacycline (Nuzyra), a broad-spectrum antibiotic approved for community-acquired pneumonia and skin infections. As a larger antibiotic player with regulatory and commercial infrastructure, serves as a comparable model for the commercial path Flightpath would need to traverse post-approval.
• Melinta Therapeutics: Established antibiotic developer with approved products (delafloxacin, oritavancin) targeting resistant gram-positive and gram-negative infections. Comparable commercial-stage antimicrobial business model and provides a reference point for what a scaled antibiotic company looks like once Flightpath's candidates reach approval.

Emerging players

• Nabriva Therapeutics: Small-cap developer of antibiotics for resistant community-acquired infections (lefamulin, CONTEPO). Comparable clinical-stage antibiotic business with similar go-to-market challenges and small operating footprint, providing a meaningful but partial overlap with Flightpath's commercial trajectory.
• Seres Therapeutics: Pioneer in microbiome therapeutics (VOWST was the first FDA-approved oral microbiome therapeutic). Competes with Flightpath in the bacterial-driven disease space but from the opposite direction — adding beneficial consortia rather than selectively removing pathogens. Comparable clinical-stage biotech focused on microbiome-linked indications including IBD.
• Vedanta Biosciences: Clinical-stage developer of defined bacterial consortia designed to modulate the gut microbiome for CDI, IBD, and food allergy. Operates in the same 'microbiome-targeting for complex disease' strategic space as Flightpath but with a different mechanism, making it a meaningful but partial comparator.
• Locus Biosciences: Develops engineered bacteriophage therapies that selectively kill specific pathogens (E. coli in UTI, S. aureus in chronic rhinosinusitis). Shares Flightpath's 'targeted bacterial deletion' strategic paradigm — precision removal of specific pathogens while sparing microbiota — though via phage rather than small molecules, making it a strong conceptual peer.

Others

• MaaT Pharma: Euronext-listed developer of microbiome-based therapeutics for oncology, GvHD, and infectious disease. Operates from a microbiome-modulation paradigm in indications that overlap partially with Flightpath's bacterial-driven disease targets, including oncology-supportive care where microbiome composition affects patient outcomes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/flightpath-biosciences-inc
• Xx.com/FlightpathB

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flightpath Biosciences